SelectQuote (SLQT) Earnings Call: Growth Amid Headwinds

SelectQuote Inc ((SLQT)) has held its Q2 earnings call. Read on for the main highlights of the call.

SelectQuote Balances Strong Execution With New Headwinds in Latest Earnings Call

Management struck a cautiously optimistic tone on SelectQuote’s latest earnings call, underscoring strong operational execution and accelerating cash generation despite acknowledging meaningful near‑term headwinds. Double‑digit revenue growth, near‑record profitability in the senior segment, and rapid expansion of the SelectRx pharmacy business were framed as evidence that the core model is working. At the same time, a pair of discrete shocks—a pharmacy benefit reimbursement adjustment and a sudden marketing pullback by a major carrier—forced the company to trim its fiscal 2026 guidance and highlighted broader uncertainty from industry disruption and preliminary government rate signals. Overall, leadership argued that structural improvements in margins, cash flow, and the balance sheet outweigh these largely one‑time pressures and support a positive long‑term outlook.

Consolidated Revenue Growth

SelectQuote reported consolidated revenue of $537 million for the quarter, a 12% year‑over‑year increase that reflects broad‑based growth across its segments. Management highlighted this double‑digit expansion as proof that the company is gaining traction even in a volatile healthcare and insurance environment. The pace of growth suggests SelectQuote is successfully leveraging its diversified platform—spanning senior, healthcare services, and life insurance—to offset isolated pressures in individual lines of business.

Senior Segment Profitability and Volume

The senior segment, SelectQuote’s core franchise, delivered revenue of $262 million, up 2% year‑over‑year, with approved policy volume rising 4%. More striking was profitability: senior adjusted EBITDA reached $102 million, translating into a near‑record 39% margin. This marks the fourth consecutive Annual Enrollment Period with margins above 30%, a performance that management presented as structural rather than cyclical. The combination of modest top‑line growth and robust margins indicates that the segment is increasingly efficient and well‑positioned to generate consistent cash.

Agent Productivity and Retention

Operationally, SelectQuote emphasized strength in its agent force as a key driver of profitability. Agent retention remained above 90%, a level that supports continuity and reduces training and recruiting costs. Productivity per agent is now 12% higher than it was two years ago, even with a larger mix of new hires in the workforce. Management attributed this to better training, data‑driven lead allocation, and optimized workflows, arguing that these productivity gains are a durable competitive advantage in a highly regulated, service-driven market.

Marketing Efficiency

Marketing efficiency remained a bright spot in the quarter. The company held marketing cost per approved policy at $326, essentially flat versus last year and roughly 20% lower than in the second quarter of 2024. This improvement in unit economics means SelectQuote is spending less to secure each policy while sustaining growth, directly supporting the elevated EBITDA margins in the senior segment. Management suggested that disciplined marketing spend and more precise targeting will be critical in navigating industry disruptions and carrier-specific volatility.

Health Care Services (SelectRx) Rapid Growth

SelectRx, the company’s healthcare services and medication management arm, continued to scale rapidly. Membership climbed 17% year‑over‑year to 113,000, while revenue surged 26% to $231 million as cohorts of onboarded members matured and began consuming their full prescription regimens. Management positioned this performance as evidence that the SelectRx model deepens customer relationships and adds a recurring, high‑value revenue stream that is less tied to annual enrollment cycles.

Clinical Outcomes and Operational Impact of SelectRx

Beyond revenue, SelectRx is beginning to show measurable clinical and cost outcomes. Pharmacists identified nearly 50,000 potential dosage or adverse drug interaction issues in 2025, resulting in tens of thousands of prescription changes. According to management, this intervention has been associated with a 20% reduction in hospital days for beneficiaries linked to improved medication adherence. These outcomes bolster SelectQuote’s value proposition with payors and partners and may reinforce long‑term relationships, particularly as the healthcare system increasingly rewards improved outcomes and reduced utilization.

Improved Capital Flexibility

On the balance sheet, SelectQuote secured a new $415 million credit facility in January that extends debt maturities out to 2031. The facility boosts peak season liquidity, giving the company more breathing room during capital‑intensive enrollment periods. It also provides potential to lower borrowing costs by up to 100 basis points over time and creates capacity to fund strategic initiatives in healthcare services and other growth areas. Management emphasized that this structure meaningfully improves visibility and financial flexibility, a key consideration given the industry’s regulatory and reimbursement uncertainties.

PBM Multiyear Agreement

Complementing the new credit facility, SelectQuote entered into a multiyear agreement with a pharmacy benefit manager that clarifies future drug reimbursement terms for SelectRx. This agreement is intended to provide much greater visibility into reimbursement pricing, reducing a major source of earnings volatility for the healthcare services business. Management framed the deal as central to supporting sustainable profitability and predictability for SelectRx after the one‑time reimbursement headwinds that hit the current outlook.

Cash Flow Improvement

Despite trimming earnings guidance, SelectQuote is projecting a notable improvement in cash generation. Management expects operating cash flow of $25 million to $35 million for fiscal 2026, with the midpoint more than $40 million higher than the prior year. They also forecast roughly 20% growth in cash EBITDA year‑over‑year. These metrics suggest that working capital dynamics and underlying unit economics are improving even as accounting-based profitability temporarily absorbs external shocks.

Life Insurance Performance

The life insurance segment continued to quietly add diversification and cash flow. Life revenue grew 9% to $44 million, supported by a 24% year‑over‑year increase in final expense premiums. Life adjusted EBITDA was $6 million, and while management noted some pressure on margins, the business still delivers attractive returns. The life segment’s steady contribution helps balance the company’s exposure to Medicare-centric volatility and supports overall cash generation.

Guidance Reduced Due to Aggregate $40 Million Headwind

The most significant negative development of the call was a reset in fiscal 2026 expectations. Consolidated revenue guidance was revised to a range of $1.61 billion to $1.71 billion, with adjusted EBITDA now expected between $90 million and $100 million. The reduction is driven by an aggregate ~$40 million headwind: roughly $20 million tied to pharmacy benefit reimbursement changes and another $20 million stemming from a national carrier’s decision to cut marketing spend in third‑party channels. Management characterized these as discrete and largely non‑recurring shocks but acknowledged the near‑term hit to earnings.

Quarterly EBITDA Temporarily Depressed by PBM Reimbursement Headwind

Healthcare services EBITDA was notably weaker in the quarter due to the previously disclosed PBM reimbursement change, which management continues to describe as a one‑time fiscal 2026 issue of approximately $20 million. While this adjustment temporarily depresses profitability, executives stressed that the new multiyear PBM agreement and the underlying growth trajectory of SelectRx should restore earnings momentum in subsequent periods. The message to investors was that the current drag is more accounting reset than structural deterioration.

National Carrier Marketing Pullback

A second major headwind came from a large national carrier that sharply reduced its strategic marketing budgets across third‑party distribution partners, including SelectQuote. The company estimates the impact at around $20 million for fiscal 2026, introducing incremental near‑term revenue risk tied to that partner. Management noted that while this disruption is meaningful on a one‑year view, SelectQuote’s diversified carrier relationships and improving marketing efficiency help mitigate the longer‑term impact, and they see opportunities to rebalance volume across the broader carrier panel.

Industry Disruption and Plan Terminations

The broader Medicare landscape remains unsettled. Carriers terminated about 7% of plans in each of the past two seasons, a sharp increase from the historical rate of less than 1%. At the same time, most beneficiaries experienced a negative change in at least one plan benefit. These dynamics have fueled elevated shopping behavior and heightened volatility, creating both risk and opportunity for brokers like SelectQuote. While the churn can pressure service and enrollment operations, it also increases the number of consumers in the market seeking advice and potentially bolsters long‑term demand for an advisory-led model.

Health Care Services Membership Outlook Moderation

In light of the reimbursement reset and a renewed focus on profitability, SelectQuote is tempering its membership expectations for SelectRx. Management now anticipates that healthcare services membership will end fiscal 2026 flat to modestly down from the current 113,000 members. The strategy is to prioritize cash flow and margin expansion over aggressive enrollment growth, especially in an environment where clarity on reimbursement and regulatory conditions is still emerging. This pivot suggests a more disciplined growth profile that favors quality over quantity of members.

Life Segment Margin Pressure

While the life business grew revenue, profitability was not immune to competition. Life adjusted EBITDA, at $6 million, was down modestly year‑over‑year as marketing expenses ticked higher and competition intensified in the Term Life space. Management indicated that despite this pressure, the segment continues to produce attractive returns and cash flow. Investors will be watching whether the company can protect margins through pricing, product mix, and marketing discipline as competitive intensity persists.

Regulatory and Rate Uncertainty

Adding to the backdrop of volatility, preliminary government rate guidance for 2027 came in softer than the industry had hoped, raising questions about future reimbursement levels. Management highlighted widespread concern across carriers and distributors and emphasized that visibility will remain limited until final rates are published later in the spring. This regulatory overhang is a key macro risk factor for the Medicare ecosystem and could influence carrier strategies, plan design, and marketing budgets in ways that affect SelectQuote’s growth profile.

Forward-Looking Guidance and Strategic Outlook

Looking ahead, SelectQuote narrowed its fiscal 2026 outlook to consolidated revenue of $1.61 billion to $1.71 billion and adjusted EBITDA of $90 million to $100 million after incorporating roughly $40 million in identified headwinds. Even with these cuts, the company expects operating cash flow between $25 million and $35 million, implying more than a $40 million improvement at the midpoint versus last year and about 20% growth in cash EBITDA. Management reiterated long‑term targets, including 20%‑plus EBITDA margins for the senior division and an annualized adjusted EBITDA exit run‑rate of $40 million to $50 million for healthcare services. They also expect SelectRx revenue to grow more than 20% year‑over‑year in fiscal 2026, even as membership remains flat to slightly down. The new $415 million credit facility, with maturities extended to 2031 and potential rate reductions, underpins this outlook by enhancing liquidity and financial flexibility.

In summary, SelectQuote’s latest earnings call painted a picture of a company executing well operationally and structurally improving its cash generation, yet forced to navigate meaningful near‑term turbulence. Strong senior segment margins, rapid healthcare services growth, and improved balance sheet flexibility provide a solid foundation. However, reimbursement resets, carrier marketing cuts, and regulatory uncertainty temper the near‑term growth story and inject volatility into forecasts. For investors, the key question is whether the demonstrated gains in efficiency, profitability, and cash flow can carry the stock through a transitional year toward the more favorable long‑term profile management envisions.